Viva Biotech (01873.HK) Surges Over 7% on Strategic Collaboration with DeepModeling for AI4S-Driven Targeted RNA Small Molecule Drug Discovery

According to the Zhicheng Finance APP, Viva Biotech (01873) rose over 7%. As of press time, it increased by 7.25%, trading at HK$1.48, with a turnover of HK$11.4331 million.

On the news front, recently, Viva Biotech and DP Technology (referred to as "DP Technology") announced a strategic partnership. Based on the synergy and complementarity of their respective businesses and technologies, the two parties will fully integrate their advantageous resources to engage in an in-depth collaboration on AI4S-based targeted RNA small molecule drug discovery. The two parties will further enhance the efficiency of RNA small molecule drug screening and discovery.

Industrial Securities previously pointed out in a research report that the company's CRO business continues to experience high growth, CDMO capacity is gradually being released, and future integration is accelerating. The company is also continuously strengthening its CMC capabilities. It is optimistic about the company’s future development of a comprehensive CRO-CDMO integrated platform. The synergy between various businesses is gradually increasing, and the引流effect of front-end projects will also gradually become apparent. Combined with the incremental effect of the EFS model, the company's revenue is expected to continue its high growth trend.